Assessing disease experience across the life span for individuals with osteogenesis imperfecta: Challenges and opportunities for patient-reported outcomes (PROs) measurement: A pilot study
Orphanet Journal of Rare Diseases
Health-related quality of life (HRQoL); Osteogenesis imperfecta; Patient reported outcomes; Patient-reported outcome measurement information system® (PROMIS®); Pediatric outcomes data collection instrument (PODCI); Rare disease; Registry
© 2019 The Author(s). Background: Patient reported outcome (PRO) information is crucial for establishing better patient-provider communication, improving shared decision-making between clinicians and patients, assessing patient responses to therapeutic interventions, and increasing satisfaction with care. We used the Brittle Bones Disease Consortium (BBDC) Contact Registry for People with OI, managed by the Rare Disease Clinical Research Network (RDCRN) to (1) to evaluate the construct validity of the Patient-Reported Outcome Measurement Information System® (PROMIS®) to record important components of the disease experience among individuals with OI; and (2) explore the feasibility of using a registry to recruit individuals with OI to report on health status. Our long-term goal is to enhance communication of health and disease management findings back to the OI community, especially those who do not have access to major OI clinical centers. Results: We demonstrated the construct validity of PROMIS instruments in OI. Our results confirm that the scores from most domains differ significantly from the general US population: individuals with OI have worse symptom burden and functioning. We found no excessive floor or ceiling effects. Our study demonstrates that the BBDC Contact Registry can be used to recruit participants for online health status surveys. However, there are numerous challenges that must be addressed: lack of self-knowledge of OI type, under-representation of men, limited ethnic diversity, and imperfect questionnaire completion rates. Conclusion: Our pilot study demonstrated the feasibility of using a contact registry to recruit respondents from the OI community and to obtain analyzable PROMIS data regarding disease experience. Because the results differ from the general population and avoid excessive floor and ceiling effects, PROMIS instruments can be used to assess response to therapeutic interventions in individuals with OI. Future directions will include (1) development and validation of an OI-specific patient-based classification system that aggregates persons with similar clinical characteristics and risks for complications to identify treatment needs; and (2) integrating these PRO tools into routine patient care and research studies.
Tosi, L., Floor, M., Dollar, C., Gillies, A., Lee, B., Nagamani, S., Rauch, F., Glorieux, F., Retrouvey, J., Esposito, P., Rush, E., Bober, M., Eyre, D., Gomez, D., Harris, G., Jain, M., Krakow, D., Orwoll, E., Raggio, C., Smith, P., Hart, T., Cuthbertson, D., Sutton, V., & Krischer, J. (2019). Assessing disease experience across the life span for individuals with osteogenesis imperfecta: Challenges and opportunities for patient-reported outcomes (PROs) measurement: A pilot study. Orphanet Journal of Rare Diseases, 14 (1). http://dx.doi.org/10.1186/s13023-019-1004-x